[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genomics":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100642220","evaluation-of-the-effectiveness-of-the-genomics--science-dojo-30-learning-method-in-improving-research-skills-and-scientific-writing-among-researchers-in-indonesia-100642220",false,"NCT07607301","Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Method in Improving Research Skills and Scientific Writing Among Researchers in Indonesia","Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Method in Improving Research Skills and Scientific Writing Among Researchers in Indonesia: A Randomized Controlled Trial","DOJO","Inclusion Criteria:\n\n* Registered participants of Genomics \\& Science DOJO 3.0\n* Teams consisting of two members\n* Submission of research concept note\n* Completion of screening and assessment stages (administratively and substantially through blind concept note screening and team's curriculum vitae)\n* Willingness and commitment to participate in the full program will be ensured through a structured confirmation process.\n* In addition, participants will be required to review, sign, and submit a commitment letter outlining the full schedule, expectations for attendance, and participation requirements.\n* Information regarding program schedule and participation expectations will be communicated at multiple stages, including during registration, program launch, and post-selection, to ensure participants are fully informed prior to confirming their participation.\n* Involvement\u002F attendance of the first author\n\nExclusion Criteria:\n\n* Incomplete registration or documentation\n* Failure to meet team composition requirements\n* Withdrawal before intervention\n* Incomplete baseline data",true,"ALL",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to rigorously evaluate the effectiveness of the DOJO 3.0 learning methodology in enhancing research skills and scientific writing among researchers in Indonesia compared to non-DOJO learning method. The main questions it aims to answer are:\n\nHow effective is the Dojo 3.0 methodology in improving participants' research skills and scientific writing, including critical thinking, data analysis ability, knowledge acquisition, and scientific manuscript quality and publication progress? How do participants' experiences, perceptions of the learning process and teaching quality, as well as their engagement, performance, and learning behaviors, differ between the intervention (DOJO) and control groups throughout the program?\n\nResearchers will compare two groups, control group and intervention group to see if there is a significant difference between these two groups.\n\nStandard learning method Non-DOJO (Control) DOJO learning method (Intervention)\n\nFor the intervention group, participants will participate in Shinjitsu class, an interactive dynamic lecture with real time engagement, an offline minicamp session with lecture that is more intense, intentionally more provocative and dynamic, wounded healer, shinjitsu ninja obstacles, shinjitsu ninja run, sparring and Tournament.",[27,28,29,30,31,32,33,34,35,36],"Workshop","Critical Thinking Skill","Data Analysis Skill","Personal Empowerment","Manuscript Quality","Genomics","Science","Research Publication","Learning Methodology","Quality of Teaching",[38,39,40,41,42,43],"Learning Method","Research Skill","Scientific Writing","Critical Thinking","Randomized Controlled Trial","Genomics and Science","RECRUITING","2026-06-12",{"date":47,"type":48},"2026-06-15","ACTUAL",{"date":50,"type":48},"2026-06-04",{"date":52,"type":21},"2027-03",{"name":54,"class":55},"Summit Institute for Development, Indonesia","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":67,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100633874","integrating-tumor-genomics-and-urinary-exosomal-proteomics-to-establish-a-multi-layer-biomarker-framework-for-early-risk-stratification-and-post-treatment-surveillance-in-fresh-thyroid-cancer-patients-100633874","NCT07532356","Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients","Inclusion Criteria:\n\n* Aged 18 to 80 years\n* Newly diagnosed Papillary Thyroid Carcinoma (PTC) or highly suspected follicular thyroid neoplasms (including lesions with potential progression to poorly differentiated thyroid carcinoma)\n* Pre-operative status\n\nExclusion Criteria:\n\n* Aged \\\u003C18 or \\>80 years\n* No confirmed diagnosis of Papillary Thyroid Carcinoma (PTC)\n* No highly suspected follicular thyroid neoplasms (including lesions with potential progression to poorly differentiated thyroid carcinoma)","18 Years","80 Years",{"count":66,"type":21},100,"3 Months","OBSERVATIONAL","Thyroid cancer is the most common endocrine malignancy, and although differentiated thyroid cancer (DTC) generally confers favorable outcomes, 10-20% of patients still face substantial postoperative risks, including local recurrence, distant metastasis, and inadequate response to radioactive iodine therapy. Current risk stratification, largely based on tumor size, lymph node involvement, and histopathology, fails to adequately represent tumor heterogeneity and evolutionary changes, potentially resulting in both overtreatment and undertreatment. Next-generation sequencing (NGS) has revealed a stepwise accumulation of genomic alterations from early driver mutations (e.g., BRAF, RAS, RET\u002FPTC, PAX8-PPARG) to late-stage progression events (e.g., TERT promoter, TP53, PI3K\u002FAKT\u002FmTOR), while metastatic lesions often harbor high-risk mutations absent in primary tumors, underscoring the limitations of single-time-point tissue sampling. Furthermore, serum thyroglobulin (Tg) surveillance is hindered in patients with anti-Tg antibodies. Extracellular vesicles (EVs), particularly those obtained from urine, provide a compelling liquid biopsy modality due to their non-invasiveness, repeatability, and reduced interference by abundant serum proteins. The investigators' previous findings demonstrate that urinary exosomal peptides-including U-Ex Tg, ANXA2, TIMP, and Angiopoietin-1-correlate with malignancy, capsular invasion, and nodal metastasis, and exhibit dynamic postoperative variation, suggesting their utility in detecting molecular residual disease.\n\nThis prospective study will recruit 100 fresh thyroid cancer cases and integrate tumor genomic profiling, urinary exosomal proteomics via LC-MRM\u002FMS, and clinical phenotype assessment-including nodal involvement, subsequent therapies, and long-term outcomes-to delineate causal links between genomic drivers, proteomic execution signals, and clinical progression. The overarching aim is to establish an early risk-stratification and molecular recurrence-alerting model capable of identifying high-risk trajectories earlier than conventional approaches, thereby enhancing surveillance precision and enabling timely intervention. This multi-layered biomarker framework holds strong potential to redefine postoperative monitoring standards and advance the clinical and policy implementation of precision medicine in thyroid cancer.",[32,71,72],"Thyroid Cancer","NGS",[72,74,75,76,77],"Urinary exosomal peptides","Differentiated thyroid cancer","Molecular recurrence surveillance","Risk stratification","NOT_YET_RECRUITING","2026-04-15",{"date":81,"type":48},"2026-04-20",{"date":83,"type":21},"2026-08-01",{"date":85,"type":21},"2031-07-31",{"name":87,"class":55},"National Taiwan University Hospital",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":95,"maxAge":63,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":56},"100625010","genodrugp-2025-study-on-three-dimensional-models-derived-from-brain-tumors-in-pediatric-patients-100625010","NCT07417072","GenoDrugP 2025: Study on Three-dimensional Models Derived From Brain Tumors in Pediatric Patients","Preliminary Study With Biological Samples, Single-center, Non-profit, to Identify Biological Mechanisms and Resistance to Therapies in Three-dimensional Models Derived From Brain Tumors in Pediatric Patients.","Inclusion Criteria:\n\n* Patients aged 3-18 years with suspected brain tumours undergoing neurosurgery\n* No previous bone marrow transplants or other haematological procedures that could potentially interfere with germline analysis.\n* Patients who have not received any systemic anticancer treatment (including chemotherapy, radiotherapy or targeted therapies) prior to enrolment surgery.\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Subsequent histological confirmation of non-neoplastic brain pathology (e.g. malformations, inflammatory lesions, demyelinating processes).\n* Insufficient quantity or quality of tumour tissue or peripheral blood for the analyses required by the protocol.\n* Presence of serious clinical conditions, systemic infections or haemodynamic instability that contraindicate the collection of biological samples or inclusion in the study.","3 Years",{"count":97,"type":21},50,[24],"Central nervous system tumours are the most common solid tumours and the leading cause of cancer mortality in children, with high biological and prognostic heterogeneity. Despite advances in the 2021 WHO molecular classifications, treatment options remain limited and often ineffective in high-grade tumours. New third-generation sequencing technologies and three-dimensional models derived from patient tumours offer promising tools for more comprehensive genomic characterisation and preclinical evaluation of drug responses. However, the lack of integrated preclinical studies remains a limitation, necessitating coordinated projects to develop personalised therapeutic strategies. The study aims to investigate the genetic and biological characteristics of paediatric brain tumours. To this end, tumour tissue samples taken during planned surgery and peripheral blood samples will be analysed. Advanced genetic analyses will be performed on these materials to identify tumour alterations and the patient's genetic characteristics. In addition, experimental in vitro models derived from the tumour will be developed to evaluate the response to different chemotherapy drugs. The information obtained will be used to better understand the mechanisms of tumour growth and resistance and to promote the future development of more targeted and personalised therapies.",[101,32,102],"Pediatric Brain Tumors","Epigenetic","2026-02-10",{"date":105,"type":48},"2026-02-18",{"date":107,"type":48},"2025-10-21",{"date":109,"type":21},"2026-10",{"name":111,"class":55},"Meyer Children's Hospital IRCCS"]